---
layout: default
title: "Case PPEGC-2025-0001"
---

# Case PPEGC-2025-0001

**Submitting Institute:** European institution (EUR-047), France  
**Publication Date:** February 15, 2025  
**DOI:** 10.ppegc/2025-0001

---

## Clinical Information

| | |
|---|---|
| **Cancer Type** | Non-small cell lung cancer (Adenocarcinoma) |
| **Stage** | Stage IV |
| **Patient Age Range** | 65-70 years |
| **Sex** | Female |
| **Treatment** | Osimertinib 80mg daily |
| **Prior Lines** | Second-line (post-platinum chemotherapy) |

---

## Genomic Profile

| Gene | Variant (HGVS) | VAF | Type |
|---|---|---|---|
| EGFR | NM_005228.5:c.2573T>G (p.Leu858Arg) | 42% | Somatic |
| EGFR | NM_005228.5:c.2369C>T (p.Thr790Met) | 38% | Somatic |

**Sequencing Method:** NGS targeted panel (70 genes)

---

## Exceptional Phenotype

**Type:** Unexpected therapeutic response (Exceptional responder)

**Description:**  
Patient with metastatic NSCLC harboring EGFR L858R + T790M mutations treated with osimertinib as second-line therapy. Despite extensive disease burden (multiple bilateral lung nodules, liver metastases, bone involvement), patient achieved complete response (CR) at 8 weeks, confirmed by PET-CT showing complete metabolic resolution.

**Timeline:**
- Baseline: Multiple liver lesions (largest 4.5cm), 15+ lung nodules
- Week 4: 70% reduction in target lesions
- Week 8: Complete radiological response (RECIST 1.1)
- Week 12: Confirmed CR by PET-CT (no FDG-avid lesions)
- Month 24: Ongoing CR (last follow-up)

**Exceptional Features:**
1. Unusually rapid response (CR at 8 weeks vs typical 3-6 months)
2. Complete response maintained >24 months (90th percentile for this mutation profile)
3. Minimal toxicity (Grade 1 skin rash only)

**Clinical Outcome:** Patient remains in complete response at 24 months with excellent quality of life.

---

## Key Insights

- Suggests potential subgroup of EGFR L858R+T790M patients with exceptionally favorable prognosis on osimertinib
- May warrant investigation of additional biomarkers predicting exceptional response
- Patient declined participation in tumor sequencing study; no additional molecular profiling available

---

## Interested in this case?

üìß **Request contact with the submitting clinician**  
[Contact PPEGC](mailto:curation@ppegc.org?subject=Contact%20Request%20-%20PPEGC-2025-0001)

üìù **Report a similar case**  
[Submit your case](https://redcap.link/ppegc-submit)

ü§ù **Propose a research collaboration**  
[Collaboration inquiry](mailto:research@ppegc.org?subject=Collaboration%20-%20PPEGC-2025-0001)

---

## Citation

**Recommended citation:**
```
European Contributor. (2025). NSCLC with EGFR L858R+T790M and exceptional 
osimertinib response. Platform for Exceptional Genomic Cancer Cases (PPEGC). 
DOI: 10.ppegc/2025-0001
```

---

## Related Cases

- [PPEGC-2025-0003](#) ‚Äî EGFR exon 19 deletion with unusual resistance pattern
- [PPEGC-2025-0007](#) ‚Äî EGFR C797S emergence after osimertinib

---

*Published: February 15, 2025*  
*Last updated: February 15, 2025*

[‚Üê Back to all cases](../cases.html) | [Home](../index.md)
